traneurocin oral (NA-831) / Biomed Industries - LARVOL DELTA

Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer's Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke (CTAD 2026) - No abstract available

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Genetic Disorders • Ischemic stroke • Obesity

Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease (CTAD 2026) - No abstract available

Clinical • P2 data • Alzheimer's Disease • CNS Disorders

AI-Enabled Analysis of Anti-Aβ Clinical Trial Outcomes Supports Investigation of the NeurogenesisBased Therapeutic Candidate NA-831 for Alzheimer's Disease (CTAD 2026) - No abstract available

Clinical • Alzheimer's Disease • CNS Disorders

Developing Topics. (PubMed, Alzheimers Dement) - P1, P2 | "The clinical findings of NA-831 and NA-931 support a potential mechanistic link between Alzheimer's disease and metabolic disorders such as obesity and diabetes. While these results are encouraging, further studies are warranted to elucidate whether this association is causal."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • IGF1

Developing Topics. (PubMed, Alzheimers Dement) - "The minimal differences between treatment and placebo-relative to the wide scoring scales-suggest that targeting amyloid plaques may be insufficient as a disease-modifying approach. These findings underscore the urgent need for alternative strategies. One such approach is NA-831, Biomed's novel small-molecule therapy based on neurogenesis and neuroprotection. Unlike amyloid-targeted antibodies, NA-831 aims to restore neuronal function and cognition by stimulating endogenous brain repair mechanisms. These emerging strategies may better align with the complex pathophysiology of AD and represent a promising new frontier in treatment."

Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia

Developing Topics. (PubMed, Alzheimers Dement) - P2, P2/3 | "These findings support a potential mechanistic link between Alzheimer's disease and Rett syndrome. Both NA-831 and NA-921 show promise as novel, well-tolerated therapeutic agents. Further studies are warranted to validate these results and deepen our understanding of the shared molecular pathways between this neurodegenerative and neurodevelopmental disorder."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • Movement Disorders • Psychiatry

Developing Topics. (PubMed, Alzheimers Dement) - "Final results from the Phase 3 study will be announced upon completion. The findings are expected to provide valuable insights into the safety and efficacy of combination therapy with NA-831 and donanemab for early Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke (CTAD 2025) - No abstract available

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders

A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Evaluate Safety and Efficacy of NA-831 as Monotherapy and in Combination with Donanemab in Subjects with Early Alzheimer's Disease (CTAD 2025) - No abstract available

Clinical • Clinical protocol • Combination therapy • Monotherapy • P3 data • Alzheimer's Disease • CNS Disorders

Translational Progress of NA-831, NA-911, and NA-931: Clinical Evidence Supporting a Unified Theory for Alzheimer's Disease, Stroke, and Obesity (CTAD 2025) - No abstract available

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Genetic Disorders • Obesity

Associations Between Alzheimer's Disease and Obesity: Clinical Trials of NA-831 for AD and NA-931 for the Treatment of Obesity (CTAD 2025) - No abstract available

Clinical • Alzheimer's Disease • CNS Disorders • Genetic Disorders • Obesity

Associations Between Alzheimer's (AD) and Obesity: Phase 2 of NA-831 for AD and NA-931for Obesity (OBESITY WEEK 2025) - P2 | "Both NA-831 and NA-931 showed promising clinical outcomes in their respective target populations, with unexpected weight loss benefits observed in the AD trial. These findings point to a potential biological link between Alzheimer's disease, obesity, and metabolic disorders like diabetes. Further research is warranted to clarify the nature and direction of this relationship."

P2 data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Diabetes • Genetic Disorders • Mental Retardation • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease • Psychiatry • Schizophrenia • IGF1

Biomed Industries to Present Four Studies at AAIC 2025 on Breakthrough Alzheimer’s, Rett Syndrome, and Obesity Therapies (Firstwordpharma Press Release) - "Biomed Industries...announced it will present four major scientific papers at the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada...Featured AAIC 2025 Presentations: 1. The End of the Amyloid Era? Evidence for a Paradigm Shift in the Quest to Treat Alzheimer’s Disease; 2. A Phase 3 Clinical Protocol of NA-831 Combined with Donanemab in Early Alzheimer’s Disease: A Placebo-Controlled, Double-Blind Study; 3. Associations Between Alzheimer’s Disease and Rett Syndrome: Clinical Trials of NA-831 and NA-921; 4. Neuro-Metabolic Link Between Alzheimer’s Disease and Obesity: Clinical Evaluation of NA-831 and NA-931"

Clinical protocol • Trial status • Alzheimer's Disease • CNS Disorders • Obesity

Developing Topics. (PubMed, Alzheimers Dement) - "The Neurogenesis Hypothesis has been shown to be a viable approach for further research for Alzheimer's disease and Major Depressive Disorder. Phase 3 trials of NA-831 for the treatment of AD and MDD are being conducted. Results of the clinical trials will be provided as soon as they are available."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Developing Topics. (PubMed, Alzheimers Dement) - "An association of Alzheimer's disease and diabetes obesity has been suggested with clinical results of NA-831 and NA-931. However, whether this association is causal requires further evaluation."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • IGF1

Developing Topics. (PubMed, Alzheimers Dement) - "An association of Alzheimer's disease and stroke has been suggested with clinical studies of NA-831 and NA-911. However, whether this association is causal requires further evaluation."

Clinical • Journal • Alzheimer's Disease • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • IGF1

Developing Topics. (PubMed, Alzheimers Dement) - "The Phase 3 clinical trial will be conducted more than 30 sites in the US and several countries. The details of the Phase 3 methodology and protocol will be presented and discussed."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Neurogenesis Hypothesis- Clinical Trials of NA-831 for Alzheimer's Disease and NA-901 for Major Depressive Disorder (CTAD 2024) - No abstract available

Clinical • Late-breaking abstract • Alzheimer's Disease • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Combination Therapy Phase 3 Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease (CTAD 2024) - No abstract available

Clinical • Combination therapy • Late-breaking abstract • P3 data • Alzheimer's Disease • CNS Disorders

NA-831: Phase 2 Clinical Trials for Alzheimer’s Disease (EIN Presswire) - P2 | N=126 | NCT03538522 | Sponsor: Biomed Industries, Inc. | "In a phase 2 trial involving 112 participants with mild to moderate Alzheimer’s, patients received either NA-831 or a placebo for 24 weeks. The results were compelling: NA-831 significantly improved cognition, with an ADAS-Cog-13 score improvement of 4.1 points (p = 0.001). Additionally, CIBIC-Plus assessments indicated that 78% of treated patients showed improvement (p = 0.01). NA-831 was well-tolerated, with no serious adverse events."

P2 data • Alzheimer's Disease • CNS Disorders

Biomed Industries, Inc. to Present Five Pivotal Papers on Alzheimer’s Disease Therapy at AAIC 2024-Philadelphia (EIN Presswire) - "Biomed Industries, Inc. (Biomed), a leading biopharmaceutical company, announced today that it will present five scientific papers at the Alzheimer’s Association International Conference (AAIC) from July 28 to August 1, 2024, in Philadelphia. The papers to be presented include: Phase 3 Clinical Protocol: A placebo-controlled, double-blind, parallel-group study evaluating the safety and efficacy of NA-831 in combination with Lecanemab in subjects with early Alzheimer’s Disease...Phase 2 Clinical Trials of NA-831: Supporting the Neurogenesis Hypothesis in treating Alzheimer’s Disease and Major Depressive Disorder. Associations Between Alzheimer’s Disease and Obesity: Clinical studies on NA-831 for AD and NA-931 for obesity. Associations Between Alzheimer’s Disease and Stroke: Clinical studies on NA-831 for AD and NA-911 for stroke."

Clinical data • Clinical protocol • P2 data • Alzheimer's Disease • CNS Disorders • Metabolic Disorders • Obesity

Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease (AAIC 2024) - "The Phase 3 clinical trial will be conducted more than 30 sites in the US and several countries. The details of the Phase 3 methodology and protocol will be presented and discussed."

Clinical • Clinical protocol • Combination therapy • P3 data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Associations Between Alzheimer’s Disease and Obesity: Clinical Trials of NA-831 for AD and NA-931 for Obesity (AAIC 2024) - "An association of Alzheimer’s disease and diabetes obesity has been suggested with clinical results of NA-831 and NA-931. However, whether this association is causal requires further evaluation."

Clinical • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • IGF1

Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder, support the Neurogenesis Hypothesis (AAIC 2024) - "The Neurogenesis Hypothesis has been shown to be a viable approach for further research for Alzheimer’s disease and Major Depressive Disorder. Phase 3 trials of NA-831 for the treatment of AD and MDD are being conducted. Results of the clinical trials will be provided as soon as they are available."

Clinical • P2 data • Alzheimer's Disease • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Associations Between Alzheimer’s Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke (AAIC 2024) - "An association of Alzheimer’s disease and stroke has been suggested with clinical studies of NA-831 and NA-911. However, whether this association is causal requires further evaluation."

Clinical • Alzheimer's Disease • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • IGF1